Healthcare
Live Price
Offline$0.0011
+57.14% today
1Y Change
-59.09%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 236 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sorrento Therapeutics, Inc. (SRNE) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 59.1% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +18.8%, EPS growth of +6.2%, a dividend yield of 0.0%. What stands out right now is revenue +18.8%, EPS +6.2%, free cash flow -5.8% with operating margin -802.6% and ROIC -286.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SRNE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRNE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRNE Max Drawdown
-94.62%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRNE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$21.2M
-32.6% YoY
FY Net Income
-$203.5M
+43.3% YoY
Free Cash Flow
-$133.0M
+27.9% YoY
Revenue Growth
+18.8%
EPS Growth
+6.2%
Gross Margin
46.8%
Net Margin
-911.6%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 63M | 53M | 40M | 31M | 21M |
| Gross Profit | 29M | 40M | 30M | 19M | 11M |
| Operating Income | -504M | -368M | -202M | -195M | -129M |
| EBITDA | -540M | -436M | -276M | -308M | -147M |
| Net Income | -573M | -429M | -298M | -359M | -204M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 24M | 37M | 56M | 23M | 168M |
| Total Assets | 473M | 695M | 536M | 558M | 675M |
| Total Liabilities | 495M | 617M | 395M | 525M | 467M |
| Shareholder Equity | -19M | 79M | 165M | 79M | 209M |
| Total Debt | 135M | 238M | 169M | 294M | 233M |
| Net Debt | 111M | 201M | 113M | 272M | 65M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
112M
+35.4% YoY
Capital Expenditures
21M
-85.2% YoY
Free Cash Flow
133M
+27.9% YoY
Key ratios
Gross Margin
46.8%
Operating Margin
-802.6%
Net Margin
-911.6%
ROE
-1904.9%
Debt / Equity
-7.23x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.